299.2 𩺠åèç
299.2.1 é«é »èé»
299.2.1.1 Early vs Late PVE
- Early †12 mo: nosocomial (CoNS, S. aureus, fungi, GNR)
- Late > 12 mo: similar to NVE (viridans, S. gallolyticus, HACEK, Enterococcus)
299.2.1.2 Staph PVE Treatment
- Nafcillin (MSSA) or vancomycin (MRSA)
- Gentamicin à 2 wk
- Rifampin à 6 wk (biofilm penetration crucial)
299.2.1.3 Imaging
- TEE first-line
- CT cardiac for paravalvular
- FDG-PET-CT for > 3 mo post-implant
- White cell scintigraphy alternative
299.2.1.4 Surgery in PVE
- More aggressive than NVE
- HF, persistent bacteremia, abscess, fungal, MDR, recurrent embolism
- Re-do sternotomy
- Often urgent
299.2.2 ææ··æ·æ¯èŒ
| Setting | Most Common | Treatment Pearl |
|---|---|---|
| Early PVE (†12 mo) | CoNS, S. aureus, fungi, GNR | Vanc + gent + rifampin |
| Late PVE (> 12 mo) | Viridans, Strep gallolyticus, HACEK | Per culture |
| Staph PVE | S. aureus, CoNS | Vanc + gent + rifampin |
| Fungal PVE | Candida | Echinocandin + surgery + long-term suppression |
| CIED infection | CoNS, S. aureus | Device extraction + abx + re-implant |
| LVAD driveline | S. aureus, Pseudomonas | Long-term abx + debridement |
| TAVR IE | Similar to NVE/PVE | Aggressive antibiotics, surgical decision |